Future growth expectations in sales/revenue/volumes?

Expansion completion expected in first half of 2021, focusing on Roh plant debottlenecking and multipurpose plants at Dahej, which should increase output without major investments. Flexible multipurpose plants allow quick switching between products based on client contracts, aiding revenue growth. Specialty products show promise, with increased volumes expected to be fully utilized within 1.5 years. Raw material prices have decreased compared to previous years, which previously allowed volume increase despite lower top-line; future margins may improve with stabilization. Export market

Future growth expectations in earnings/operating earnings/profits/EPS?

Expansion completions expected by first half of 2021, enabling further capacity utilization and growth. Sulfuric acid and sulfone plants are undergoing validation; contracts awaited before further investment, signaling cautious growth. Debottlenecking efforts at Roha plant aim to increase output without major investments. Multipurpose plants at Dahej are operational but not at full capacity, suggesting room for ramp-up. Specialty products and new boron products are being explored to offset stagnation in borax business. Competition from China intensifies, with China providing subsidies to their

Current/ Expected Orderbook/ Pending Orders?

The company is currently facing some delay in new orders, especially on the boron side, partly due to regulatory delays such as the boric acid registration with BIS which was lost for about 4-5 months. Validation for sulfone products is complete, but actual business pickup is slower than expected due to market turmoil and reduced demand. Contracts from clients, especially for sulfone and specialty products, are pending; management is waiting for client contracts to proceed further. The company has made investments of around ₹50 crores in multipurpose plants with flexible production options, ex

Any current/future new fundraising through debt or equity?

The company currently has about ₹50 crore investments in sulfuric acid, oleum, and chlorosulfonic acid plants, and another ₹20 crore for one of the plants. They do not want to be very aggressive with borrowings under the current conditions. Further expansion and investments will depend on securing firm contracts. If certain of contracts, they will proceed with further debt or equity fundraising; otherwise, they will defer. No explicit mention of immediate new fundraising through equity or debt, but future fundraising is contingent on confirmed contracts and market conditions.

Any current/future capex/capital investment/strategic investment?

The company plans a shutdown in Q3 (typically 3 weeks to 1 month) for repairs and debottlenecking without major investment as of now, with more extensive shutdown in Oct-Dec quarter. Around ₹50 crore investment is committed in sulfuric acid and oleum and chlorosulfonic acid plants. Approximately ₹20 crore invested in multipurpose plants, with ongoing production but not yet at full capacity. Debottlenecking investments are being made at Roha plant to increase output without major capital expenditure. Further expansion is planned dependent on client contracts and market conditions, especially fo

DMCC Speciality Chemicals LtdQ4 FY20Chemicals & Petrochemicals

DMCC Speciality Chemicals Ltd Q4 FY20 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹294.7P/E: 18.4Market Cap: ₹734 CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 4

Expansion completion expected in first half of 2021, focusing on Roh plant debottlenecking and multipurpose plants at Dahej, which should increase output without major investments.
Flexible multipurpose plants allow quick switching between products based on client contracts, aiding revenue growth.
Specialty products show promise, with increased volumes expected to be fully utilized within 1.5 years.
Raw material prices have decreased compared to previous years, which previously allowed volume increase despite lower top-line; future margins may improve with stabilization.
Export market had a low in Q3 FY20 due to COVID-19 but picked up in January, indicating recovery and growth potential.
Competitive pressures from China (e.g., 13% export subsidy) will impact business but also drive market activity.
Company cautious on further borrowing, awaits firm contracts before additional investments.

Margin guidance

Category 3

Expansion completions expected by first half of 2021, enabling further capacity utilization and growth.
Sulfuric acid and sulfone plants are undergoing validation; contracts awaited before further investment, signaling cautious growth.
Debottlenecking efforts at Roha plant aim to increase output without major investments.
Multipurpose plants at Dahej are operational but not at full capacity, suggesting room for ramp-up.
Specialty products and new boron products are being explored to offset stagnation in borax business.
Competition from China intensifies, with China providing subsidies to their manufacturers; domestic growth faces challenges.
Gross margins improved recently due to raw material cost reductions and higher specialty product mix.
Management cautious on leverage and capital expenditures until contracts are secured, implying measured profit growth.
Earnings growth expected post validation and contract wins, targeting improved operational profits and EPS in coming quarters.

See what DMCC Speciality Chemicals Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

The company currently has about ₹50 crore investments in sulfuric acid, oleum, and chlorosulfonic acid plants, and another ₹20 crore for one of the plants.
They do not want to be very aggressive with borrowings under the current conditions.
Further expansion and investments will depend on securing firm contracts.
If certain of contracts, they will proceed with further debt or equity fundraising; otherwise, they will defer.
No explicit mention of immediate new fundraising through equity or debt, but future fundraising is contingent on confirmed contracts and market conditions.

Order book

The company is currently facing some delay in new orders, especially on the boron side, partly due to regulatory delays such as the boric acid registration with BIS which was lost for about 4-5 months.
Validation for sulfone products is complete, but actual business pickup is slower than expected due to market turmoil and reduced demand.
Contracts from clients, especially for sulfone and specialty products, are pending; management is waiting for client contracts to proceed further.
The company has made investments of around ₹50 crores in multipurpose plants with flexible production options, expected to be fully utilized within the next 1 to 1.5 years.
Competition from China is aggressive due to export subsidies, impacting market share and contract inflow.
Because of uncertainties, management prefers to defer further leverage until contracts are secured.

See what DMCC Speciality Chemicals Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

The company plans a shutdown in Q3 (typically 3 weeks to 1 month) for repairs and debottlenecking without major investment as of now, with more extensive shutdown in Oct-Dec quarter.
Around ₹50 crore investment is committed in sulfuric acid and oleum and chlorosulfonic acid plants.
Approximately ₹20 crore invested in multipurpose plants, with ongoing production but not yet at full capacity.
Debottlenecking investments are being made at Roha plant to increase output without major capital expenditure.
Further expansion is planned dependent on client contracts and market conditions, especially for sulfuric acid and sulfone products.
The company is cautious about aggressive borrowing and will proceed with new investments only when contracts are certain (clarity expected by August-September).
Expansion completion timelines have shifted to the first half of 2021 from 2020 due to delays.

Track DMCC Speciality Chemicals Ltd — get its next earnings analysis in your feed

How does DMCC Speciality Chemicals Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisDMCC Speciality Chemicals Ltd

Rev 4Mar 3

See where DMCC Speciality Chemicals Ltd sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does DMCC Speciality Chemicals Ltd rank in Chemicals & Petrochemicals?

Compare DMCC Speciality Chemicals Ltd against every Chemicals & Petrochemicals company (Q4 FY20) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What DMCC Speciality Chemicals Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Alufluoride Ltd (Q1 FY27)
Revenue from operations for Q1 FY27 was ₹26.6 crore, down 39% YoY (Page 6, 7, 8). Key investor presentation takeaways from Alufluoride Ltd's Q1 FY27 investor pr
POCL Enterprises Ltd (Q1 FY27)
466.03 crores (Page 12, 17, 11) . Key investor presentation takeaways from POCL Enterprises Ltd's Q1 FY27 investor presentation — and how it ranks against secto
Deepak Nitrite Ltd (Q2 FY27)
Q2 FY27 total revenue: ₹3,091 crore, up 61% YoY (Page 1, 4, 5, 6, 10, 11) . Key investor presentation takeaways from Deepak Nitrite Ltd's Q2 FY27 investor prese
Privi Speciality Chemicals Ltd (Q2 FY27)
19,239.47 lakhs (approximately 33.9% growth). Key results statement takeaways from Privi Speciality Chemicals Ltd's Q2 FY27 results statement — and how it ranks

Compare:vs Solar Industries vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →